What Bio-Fence does

Bio-Fence Ltd. is a privately held Israeli company founded in 2017 and headquartered in Jerusalem, focused on reducing morbidity and mortality from contaminated surfaces in healthcare and food-safety settings. The company has developed and commercialized a single product, OxiLast™ — a patented, water-based, film-forming antimicrobial coating formulation that is mixed with chlorine-based disinfectants and wipe-applied to non-porous, high-touch surfaces such as bed rails, bedside tables, mattresses, IV stands, light switches, door handles, and wheelchairs. The film preserves and extends the bactericidal capacity of chlorine during prolonged gaps between disinfection cycles, providing residual antimicrobial protection for up to 7 days and demonstrating ≥99.99% reduction of ESKAPE pathogens (MRSA, VRE, CRE, Pseudomonas aeruginosa, Acinetobacter baumannii) and Candida Auris within 5–15 minutes under challenging conditions including organic contamination and successive bacterial loadings.

The company has built scientific credibility through two core collaborations: in vitro efficacy studies at the Moran-Gilad Lab at Ben-Gurion University (resulting in a published Aric 2023 article) and a clinical effectiveness study at Hadassah Medical Center comparing OxiLast to the hospital's standard sanitation protocol against MRSA and Klebsiella pneumoniae on patient-room surfaces. Bio-Fence operates a B2B direct-sales motion initiated through structured website inquiry forms, with global country coverage and no publicly disclosed pricing. Revenue is generated via one-time product sales under a single-product line. The company has 1–10 employees, no disclosed external funding, no disclosed management team, and no disclosed commercial customers or revenue, indicating an early-stage, validation-phase commercial posture.

Name

Bio-Fence

Legal name

Bio-Fence Ltd.

Website

https://bio-fence.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Bio-Fence Ltd. is a privately held Israeli company founded in 2017 that develops OxiLast™, a patented water-based antimicrobial coating extending chlorine's residual bactericidal activity for up to 7 days on high-touch surfaces in healthcare facilities and food-safety environments.

Ownership category

akta.pro rank

Product category

Antimicrobial Surface Coatings / Infection Prevention Products

SIC

Specialty Cleaning, Polishing And Sanitation Preparations (2842)

akta.pro primary industry

Concentrated Surface Disinfectants (Dilutable Liquids) (CRAJANAB)

akta.pro secondary industry

Disinfecting All-Purpose Cleaners (CRAJAMAB)

Keywords

• Antimicrobial coatings
• Surface disinfection
• Infection prevention
• Healthcare hygiene
• Antimicrobial film technology

Headquarters

HQ city

Ashdod

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales

Revenue model

1. OxiLast Antimicrobial Coating Product Sales: Bio-Fence generates revenue through the sale of their OxiLast patented antimicrobial coating product. The product is a film-forming formulation that is diluted with water and combined with chlorine tablets for application to surfaces in healthcare and food safety settings. The product is applied using a wipe-on method to inanimate non-porous surfaces.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Bio-Fence develops and sells OxiLast, a patented water-based film-forming antimicrobial coating formulation designed to be added to chlorine-based disinfecting solutions. The product creates an invisible temporary film on surfaces that preserves and extends the bactericidal capacity of chlorine during prolonged gaps between disinfection cycles, delivering up to 7 days of residual protection against healthcare-associated pathogens. The wipe-on product is intended for high-touch non-porous surfaces in healthcare facilities and food safety environments.

Product overview

Bio-Fence is a single-product company focused on healthcare infection prevention. Their flagship offering is OxiLast™, a patented antimicrobial coating technology that stabilizes chlorine-based disinfectants onto surfaces, creating a residual protective film that provides long-lasting antimicrobial activity for up to 7 days. The product is designed for healthcare settings to reduce healthcare-associated infections (HAIs) and combat antimicrobial resistance (AMR).

Differentiator

Problem solved

Functional benefit

Brands

• OxiLast: Patented coating material that creates a long-lasting antimicrobial film, added to chlorine-based disinfecting solutions to preserve and extend bactericidal capacity for up to 7 days on surfaces.

Products and services

• OxiLast OxiLast is a patented water-based film-forming antimicrobial coating formulation designed to be diluted with water and combined with a chlorine tablet for wipe-on application to inanimate non-porous surfaces. It creates an invisible temporary film that preserves and extends the bactericidal capacity of chlorine during prolonged gaps between disinfection cycles, delivering up to 7 days of residual antimicrobial activity against ESKAPE pathogens and Candida Auris. Intended for high-touch surfaces in healthcare facilities (patient rooms, bed rails, bedside tables, mattresses, IV stands, light switches, door handles, wheelchairs) and food safety environments.

Quantifiable outcome

• >=99.99% reduction of ESKAPE pathogens (E. coli, MRSA, VRE, CRE, Pseudomonas aeruginosa, Acinetobacter baumannii) within 5-15 minutes, lasting up to 7 days
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Ben-Gurion University (Moran-Gilad Lab)coreStrategic or Co-development PartnerBio-Fence collaborated with the Moran-Gilad Lab at Ben-Gurion University to conduct comprehensive in vitro studies testing OxiLast's efficacy against ESKAPE pathogens. The studies demonstrated >=99.99% reduction of Gram positive and Gram negative ESKAPE organisms when applied to surfaces, with effectiveness lasting up to 7 days even under challenging conditions including simulated abrasion, organic contamination, and successive inoculations. Prof. Moran-Gilad (Prof. of Public Health and Clinical Microbiology) endorsed the technology as potentially being 'a game changer in the prevention of resistant infections.'
• Hadassah Medical CentercoreStrategic or Co-development PartnerThe Hadassah Medical Center conducted a clinical effectiveness study of OxiLast in killing MRSA and Klebsiella pneumoniae on surfaces in actual patient rooms. Surfaces were treated once on day 0 (D0) and then contaminated with 106 CFU of resistant bacteria on consecutive days until day 7 (D7). The study compared OxiLast effectiveness against the hospital's current sanitation protocol, demonstrating significant reduction in live bacterial counts.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Emerging players

• Sciessent: Sciessent supplies antimicrobial and odor-control technologies (e.g., Agion) integrated into materials and surfaces. Adjacent emerging player offering an alternative additive-based antimicrobial mechanism relevant to Bio-Fence's high-touch-surface thesis.
• Cupron: Cupron embeds copper-based antimicrobial technology into textiles and surfaces for healthcare and consumer applications. Comparable as an emerging player using a different antimicrobial chemistry (copper) to address the same high-touch-surface infection-prevention pain point.

Broad incumbents

• PDI Healthcare: PDI (Nice-Pak) is a leading manufacturer of disinfectant wipes (Sani-Cloth, Super Sani-Cloth) widely used in US hospitals. Comparable as an institutional disinfection incumbent with established hospital salesforce Bio-Fence must displace or partner with.
• Clorox Healthcare: Clorox Healthcare supplies disinfectants, sanitizers, and wipes used across US hospitals. A broad incumbent in healthcare surface disinfection that could leverage scale and distribution to launch a residual-efficacy competing product.
• Ecolab: Ecolab is a global leader in infection prevention, healthcare hygiene, and surface disinfection. Comparable as a major, well-capitalized incumbent with the sales reach and R&D depth to either develop or acquire residual-coating capabilities competing with Bio-Fence.

Direct peers

• Halomine: Halomine develops antimicrobial additive chemistries designed to be combined with common disinfectants to provide residual activity. Highly comparable mechanism and target use case (healthcare/food safety) to Bio-Fence's OxiLast.
• HeiQ Materials: HeiQ develops proprietary antimicrobial and hygiene technologies applied to surfaces and textiles (e.g., HeiQ Viroblock). Comparable as a residual-effect antimicrobial technology provider targeting infection prevention, with broader delivery formats than Bio-Fence.
• Allied BioScience: Allied BioScience develops long-lasting antimicrobial surface coatings (e.g., AEGIS Microbe Shield) for healthcare and high-touch environments. Directly comparable to Bio-Fence's OxiLast film-forming residual disinfection approach and target customers.
• Kastus: Kastus develops antimicrobial surface coatings that provide 24/7 protection against bacteria on glass, ceramics, and metals. Comparable technology approach (coatings delivering long-lasting antimicrobial activity) applied to shared infection-prevention pain points.
• BioProtect: Israeli antimicrobial coating company commercializing surface-protective formulations used in medical and food settings. Directly comparable as a same-region, same-product-category peer focused on residual antimicrobial film technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biofence/posts/?feedView=all

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio-Fence